-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shandong Longnuo Pharmaceutical's 4 types of generic risperidone oral solution has entered the "approval" stage, and it is expected to usher in good news in the near future
.
At present, 8 domestic companies have obtained approval for risperidone oral solution, and only 1 company has been approved according to the new classification as a review
.
.
At present, 8 domestic companies have obtained approval for risperidone oral solution, and only 1 company has been approved according to the new classification as a review
.
Figure 1: The registration progress of risperidone oral solution of Shandong Longnuo Pharmaceutical Co.
, Ltd.
, Ltd.
Source: NMPA official website
According to data from Minet.
com, in the first half of 2021 , risperidone ranked fifth among the TOP20 terminal psychotropic drugs in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
This variety is used to treat acute and chronic schizophrenia
.
com, in the first half of 2021 , risperidone ranked fifth among the TOP20 terminal psychotropic drugs in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
This variety is used to treat acute and chronic schizophrenia
.
At present, there are 4 over-evaluated products involved in risperidone.
Risperidone tablets have been included in the first batch of national procurement.
In addition, dispersible tablets (Enhua Pharmaceutical), oral solution (Anhui New Century Pharmaceutical), oral disintegrating There is only one company that has passed the evaluation of Xie Pian (Qilu Pharmaceutical)
.
Risperidone tablets have been included in the first batch of national procurement.
In addition, dispersible tablets (Enhua Pharmaceutical), oral solution (Anhui New Century Pharmaceutical), oral disintegrating There is only one company that has passed the evaluation of Xie Pian (Qilu Pharmaceutical)
.
Figure 2: Sales of risperidone oral solution (unit: ten thousand yuan)
Source: Terminal competition pattern of public medical institutions in China
The sales of risperidone oral solution in China's public medical institutions have steadily increased in recent years.
In 2020, the sales will continue to remain above 100 million yuan, and the growth rate in the first half of 2021 will be 8.
25%
.
Xi'an Janssen accounts for more than 70%, and as domestic high-end generic drugs join the competition one after another, it is expected to accelerate the realization of "replacement of original research"
.
In 2020, the sales will continue to remain above 100 million yuan, and the growth rate in the first half of 2021 will be 8.
25%
.
Xi'an Janssen accounts for more than 70%, and as domestic high-end generic drugs join the competition one after another, it is expected to accelerate the realization of "replacement of original research"
.
Table 1: Shandong Longnuo Pharmaceutical has reviewed products
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Up to now, Shandong Lonno Pharmaceutical has reviewed 5 products, which are distributed in 4 categories.
If the company's risperidone oral solution is successfully approved and deemed to have been reviewed, it is expected to become the company's first neurological drug.
Approved and reviewed products
.
If the company's risperidone oral solution is successfully approved and deemed to have been reviewed, it is expected to become the company's first neurological drug.
Approved and reviewed products
.
Recently, Shandong Longnuo Pharmaceutical's 4 types of generic risperidone oral solution has entered the "approval" stage, and it is expected to usher in good news in the near future
.
At present, 8 domestic companies have obtained approval for risperidone oral solution, and only 1 company has been approved according to the new classification as a review
.
.
At present, 8 domestic companies have obtained approval for risperidone oral solution, and only 1 company has been approved according to the new classification as a review
.
Figure 1: The registration progress of risperidone oral solution of Shandong Longnuo Pharmaceutical Co.
, Ltd.
, Ltd.
Source: NMPA official website
According to data from Minet.
com, in the first half of 2021 , risperidone ranked fifth among the TOP20 terminal psychotropic drugs in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
This variety is used to treat acute and chronic schizophrenia
.
com, in the first half of 2021 , risperidone ranked fifth among the TOP20 terminal psychotropic drugs in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
This variety is used to treat acute and chronic schizophrenia
.
At present, there are 4 over-evaluated products involved in risperidone.
Risperidone tablets have been included in the first batch of national procurement.
In addition, dispersible tablets (Enhua Pharmaceutical), oral solution (Anhui New Century Pharmaceutical), oral disintegrating There is only one company that has passed the evaluation of Xie Pian (Qilu Pharmaceutical)
.
Risperidone tablets have been included in the first batch of national procurement.
In addition, dispersible tablets (Enhua Pharmaceutical), oral solution (Anhui New Century Pharmaceutical), oral disintegrating There is only one company that has passed the evaluation of Xie Pian (Qilu Pharmaceutical)
.
Figure 2: Sales of risperidone oral solution (unit: ten thousand yuan)
Source: Terminal competition pattern of public medical institutions in China
The sales of risperidone oral solution in China's public medical institutions have steadily increased in recent years.
In 2020, the sales will continue to remain above 100 million yuan, and the growth rate in the first half of 2021 will be 8.
25%
.
Xi'an Janssen accounts for more than 70%, and as domestic high-end generic drugs join the competition one after another, it is expected to accelerate the realization of "replacement of original research"
.
In 2020, the sales will continue to remain above 100 million yuan, and the growth rate in the first half of 2021 will be 8.
25%
.
Xi'an Janssen accounts for more than 70%, and as domestic high-end generic drugs join the competition one after another, it is expected to accelerate the realization of "replacement of original research"
.
Table 1: Shandong Longnuo Pharmaceutical has reviewed products
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Up to now, Shandong Lonno Pharmaceutical has reviewed 5 products, which are distributed in 4 categories.
If the company's risperidone oral solution is successfully approved and deemed to have been reviewed, it is expected to become the company's first neurological drug.
Approved and reviewed products
.
If the company's risperidone oral solution is successfully approved and deemed to have been reviewed, it is expected to become the company's first neurological drug.
Approved and reviewed products
.
Recently, Shandong Longnuo Pharmaceutical's 4 types of generic risperidone oral solution has entered the "approval" stage, and it is expected to usher in good news in the near future
.
At present, 8 domestic companies have obtained approval for risperidone oral solution, and only 1 company has been approved according to the new classification as a review
.
.
At present, 8 domestic companies have obtained approval for risperidone oral solution, and only 1 company has been approved according to the new classification as a review
.
Figure 1: The registration progress of risperidone oral solution of Shandong Longnuo Pharmaceutical Co.
, Ltd.
, Ltd.
Source: NMPA official website
According to data from Minet.
com, in the first half of 2021 , risperidone ranked fifth among the TOP20 terminal psychotropic drugs in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
This variety is used to treat acute and chronic schizophrenia
.
hospital hospital hospitalcom, in the first half of 2021 , risperidone ranked fifth among the TOP20 terminal psychotropic drugs in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
This variety is used to treat acute and chronic schizophrenia
.
At present, there are 4 over-evaluated products involved in risperidone.
Risperidone tablets have been included in the first batch of national procurement.
In addition, dispersible tablets (Enhua Pharmaceutical), oral solution (Anhui New Century Pharmaceutical), oral disintegrating There is only one company that has passed the evaluation of Xie Pian (Qilu Pharmaceutical)
.
enterprise enterprise enterpriseRisperidone tablets have been included in the first batch of national procurement.
In addition, dispersible tablets (Enhua Pharmaceutical), oral solution (Anhui New Century Pharmaceutical), oral disintegrating There is only one company that has passed the evaluation of Xie Pian (Qilu Pharmaceutical)
.
Figure 2: Sales of risperidone oral solution (unit: ten thousand yuan)
Source: Terminal competition pattern of public medical institutions in China
The sales of risperidone oral solution in China's public medical institutions have steadily increased in recent years.
In 2020, the sales will continue to remain above 100 million yuan, and the growth rate in the first half of 2021 will be 8.
25%
.
Xi'an Janssen accounts for more than 70%, and as domestic high-end generic drugs join the competition one after another, it is expected to accelerate the realization of "replacement of original research"
.
In 2020, the sales will continue to remain above 100 million yuan, and the growth rate in the first half of 2021 will be 8.
25%
.
Xi'an Janssen accounts for more than 70%, and as domestic high-end generic drugs join the competition one after another, it is expected to accelerate the realization of "replacement of original research"
.
Table 1: Shandong Longnuo Pharmaceutical has reviewed products
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Up to now, Shandong Lonno Pharmaceutical has reviewed 5 products, which are distributed in 4 categories.
If the company's risperidone oral solution is successfully approved and deemed to have been reviewed, it is expected to become the company's first neurological drug.
Approved and reviewed products
.
If the company's risperidone oral solution is successfully approved and deemed to have been reviewed, it is expected to become the company's first neurological drug.
Approved and reviewed products
.
